Excluding any other type of skin cancer, just the focus on colorectal cancer alone is already the third leading cancer-related death in the United States. This tragedy affects both men and women. The start of this cancer begins in the rectum or colon. The portion of U.S. grownups aged 50 to 75 years who were updated with colorectal cancer screening increased by 1.4%, from 67.4% in 2016 to 68.8% in 2018. This represents an extra 3.5 million men and women evaluated for colorectal cancer.
As an investor who wholeheartedly despises any type of cancer, this company provides me with a better vision that we can combat colorectal cancer. Check-Cap ($CHEK) is a clinical-phase medical diagnostics business establishing C-Scan, which is the very first pill-based system for ease-of-use, colorectal cancer screening. C-Scan is one of Check-Cap’s biggest technology.
With their C-Scan product, the innovation behind it can truly change the way screening for cancer works. This kind of tablet capsule creates info on the shapes of the within the colon as it passes naturally. This detail is utilized to develop a 3D map which shows the colon and permits doctors to search for polyps and other problems. Developed to enhance the client experience and increase the desire of people to take part in suggested colorectal cancer screening, this item eliminates lots of regularly-cited barriers, such as laxative bowel preparation, sedation, and invasiveness.
At the time of writing this post, $CHEK currently is at above 13 million dollars in market cap. When the market closed on May 15, 2020, the value of each share closed at $0.5264 according to Yahoo Finance. As an investor for many years with a diverse range of portfolios, I can confirm that the health market is remarkably enormous.
To reassure new and potential investors, Check-Cap even has a contact page to get the much-needed information. http://ir.check-cap.com/contact-us
Their product, C-Scan is also CE certified.
After doing my thorough research of the company, they have their teams split up into three which includes the management team, board of directors, and scientific advisors. I noticed that members on the team/board have decades of health experience, which gives me hope for our future in preventing colorectal cancer. The current Chief Executive Officer, Alex Ovadia, became a part of the team back in 2013. Because of his expertise and professionalism, he started as Chief Operating Officer, became Vice President of Research, and eventually moved up to CEO. With Ovadia’s experience of over 25 years, the future is in great hands.
Here are 2020’s highlights for $CHEK on their press release:
- Check-Cap Reports 4th Quarter and 2019 Financial Results
- Check-Cap Provides Updates on COVID-19 Pandemic Impact
- Announces 4 Million Dollars Registered Direct Offering
- Announces 4.5 Million Dollars Registered Direct Offering
- Announces 3 Million Dollars Registered Direct Offering
Overall, this company unquestionably has a positive future for investors and a noble vision of fighting against colorectal cancer. Their medical product seems likely to have a positive impact on the health industry with the many years to come. The health industry alone has a market cap of over 1 trillion dollars, which is surprisingly enormous.
From an investor’s point of view, I believe that the current market cap for $CHEK is quite low and that there’s a huge room to grow. Investing can be tricky, which is why I recommend that you do your in-depth research before making any financial decision. After all, this is my opinion from an avid investor’s point of view. Before making your decision on whether to invest or not, visit http://www.check-cap.com/ for additional information. To read more about their life-changing product, you can find it at http://www.check-cap.com/technology/c-scan-technology.
Additional info about the company:
Garbage 2 Gucci 